-
Signature
-
/s/ by Mindi Zimmer, as Attorney-in-Fact For: Robert J. Mears
-
Issuer symbol
-
ATOM
-
Transactions as of
-
02 Mar 2026
-
Net transactions value
-
-$19,696
-
Form type
-
4
-
Filing time
-
03 Mar 2026, 20:51:14 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Mears Robert J |
Chief Technology Officer |
C/O ATOMERA, INC., 750 UNIVERSITY AVENUE, SUITE 280, LOS GATOS |
/s/ by Mindi Zimmer, as Attorney-in-Fact For: Robert J. Mears |
03 Mar 2026 |
0001680617 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ATOM |
Common Stock |
Sale |
$2,109 |
-426 |
-0.25% |
$4.95 |
172,452 |
02 Mar 2026 |
Direct |
F1 |
| transaction |
ATOM |
Common Stock |
Sale |
$4,272 |
-863 |
-0.5% |
$4.95 |
171,589 |
02 Mar 2026 |
Direct |
F1 |
| transaction |
ATOM |
Common Stock |
Sale |
$4,925 |
-995 |
-0.58% |
$4.95 |
170,594 |
02 Mar 2026 |
Direct |
F1 |
| transaction |
ATOM |
Common Stock |
Sale |
$8,390 |
-1,695 |
-0.99% |
$4.95 |
168,899 |
02 Mar 2026 |
Direct |
F1 |
| transaction |
ATOM |
Common Stock |
Award |
$0 |
+57,252 |
+34% |
$0.000000 |
226,151 |
02 Mar 2026 |
Direct |
F2 |
| transaction |
ATOM |
Common Stock |
Award |
$0 |
+28,626 |
+13% |
$0.000000 |
254,777 |
02 Mar 2026 |
Direct |
F3 |
| transaction |
ATOM |
Common Stock |
Award |
$0 |
+28,626 |
+11% |
$0.000000 |
283,403 |
02 Mar 2026 |
Direct |
F4 |
| holding |
ATOM |
Common Stock |
|
|
|
|
|
2,666 |
02 Mar 2026 |
by Spouse |
|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: